AMP-activated protein kinase (AMPK) is the downstream component of a protein kinase cascade that plays a major role in maintaining energy homoeostasis. Within individual cells, AMPK is activated by a rise in the AMP/ATP ratio that occurs following a fall in ATP levels. AMPK is also regulated by the adipokines, adiponectin and leptin, hormones that are secreted from adipocytes. AMPK regulates a wide range of metabolic pathways, including fatty acid oxidation, fatty acid synthesis, glycolysis and gluconeogenesis. In peripheral tissues, activation of AMPK leads to responses that are beneficial in counteracting the deleterious effects that arise in the metabolic syndrome. Recent studies have demonstrated that modulation of AMPK activity in the hypothalamus plays a role in feeding. A decrease in hypothalamic AMPK activity is associated with decreased feeding, whereas activation of AMPK leads to increased food intake. Furthermore, signalling pathways occurring in the hypothalamus lead to changes in AMPK activity in peripheral tissues, such as skeletal muscle, via the sympathetic nervous system. AMPK, therefore, provides a mechanism for monitoring changes in energy metabolism within individual cells and at the level of the whole body. Activation of AMPK requires phosphorylation of threonine 172 (Thr-172) within the catalytic subunit. Recent studies have shown that both LKB1 and Ca 2 þ /calmodulin-dependent protein kinase kinase-b (CaMKKb) play important roles in phosphorylating and activating AMPK. In addition, there is evidence that AMPK can be activated by other upstream kinases, although the physiological significance of this is not clear at present. This review focuses on the role of LKB1 and CaMKKb in the regulation of AMPK.
Introduction
Controlling energy metabolism is a fundamental requirement for all living cells. Work from a number of groups over the last few years has placed AMP-activated protein kinase (AMPK) as a key player in the regulation of energy metabolism. AMPK is activated by a rise in the AMP/ATP ratio within the cell. This ratio increases when ATP is depleted, via the action of adenylate kinase. This property, in effect, allows AMPK to act as a low energy sensor. Following activation, AMPK responds by phosphorylating downstream targets so that ATP-consuming pathways are inhibited and ATP-producing pathways are activated. In this manner, AMPK allows cells to adjust to changes in cellular energy demand (Figure 1 ). The key step in the activation of AMPK is its phosphorylation on threonine 172 (Thr-172) within its catalytic subunit. Recent studies have identified LKB1 and Ca 2 þ /calmodulin-dependent protein kinase kinase-b (CaMKKb) as two kinases that phosphorylate Thr-172. Here we discuss the role of LKB1 and CaMKKb in the regulation of AMPK and the potential physiological significance of the upstream kinases in regulating energy metabolism.
Regulation of AMPK
AMPK is a heterotrimeric complex of a catalytic subunit (a) and two regulatory subunits (b and g) and isoforms of all three subunits (a1, a2, b1, b2, g1, g2 and g3) have been identified in mammals. 1 The yeast counterpart of AMPK is the sucrose non-fermenting complex (SNF1), composed of Snf1 (a), Snf4 (g) and either Snf1-interacting protein (Sip)-1,2 or Gal-83 (b-isoforms). 2 Mammalian AMPK is allosterically activated by AMP, with the degree of activation depending on the nature of both the a-and g-subunit isoforms present in the complex. 3 The greatest degree of activation is seen in complexes containing the a2-and g2-isoforms (nearly fivefold at saturating levels of AMP). In contrast, complexes containing the g3-isoform are only weakly activated by AMP (o2-fold). 4 Additional lines of evidence suggest that the g-subunit is involved in the allosteric activation of AMPK. The g-subunit contains four cystathionine-b-synthase domains. 5 In human g2-isoform, naturally occurring mutations in these domains cause cardiac hypertrophy due to massive glycogen accumulation, together with Wolff-Parkinson-White syndrome, a preexcitation disorder. [6] [7] [8] Biochemical studies demonstrate that some of these mutations interfere with AMP-activation of AMPK. 9, 10 Furthermore, the cystathionine-b-synthase domains have been shown to bind AMP in in vitro binding assays. 10 In contrast to AMPK, allosteric activation of SNF1 by AMP has not been demonstrated. 11, 12 In addition to allosteric activation, AMPK is regulated by reversible phosphorylation. AMPK is activated by phosphorylation and catalysed by an upstream kinase, forming a bi-cyclic protein kinase cascade. 13 Quantitatively, activation by phosphorylation is much more significant than allosteric activation (41000-fold for phosphorylation compared to up to fivefold for allosteric activation). 14 Although the evidence that AMPK was regulated by phosphorylation was well established in the 1980s it took over 20 years to elucidate the molecular identity of the upstream kinases in the AMPK cascade. In the intervening period, however, it was shown that activation of AMPK involves phosphorylation of Thr-172 within the a-subunit. 15 Identification of Thr-172 as the critical residue in AMPK activation was an important step as it allowed for the generation of antibodies that recognize specifically the phosphorylated form of AMPK. These antibodies provide a key tool for monitoring AMPK activation in cells and tissues and have played a significant part in advancing our understanding of the physiological regulation of AMPK.
Identification of the upstream kinases in the AMPK cascade
Despite intensive efforts by a number of groups, the molecular identification of the upstream kinases in the AMPK cascade remained elusive, leading to a major research bottleneck in the field. The breakthrough that was to emerge came from studies in yeast. Like AMPK, SNF1 is activated by phosphorylation (on threonine 210, equivalent to Thr-172 in mammalian AMPK). Genetic studies in yeast had failed to identify a kinase upstream of SNF1 suggesting that multiple kinases act on SNF1. However, mass spectrometric analysis of yeast protein complexes identified two protein kinases, Tos3 and Sak1 (originally termed Pak1), which interacted with SNF1 subunits, making them potential candidates for SNF1 kinases. Subsequent studies by two independent groups showed that Tos3 and Sak1, along with a third closely related kinase, Elm1, phosphorylate and activate the SNF1 complex. 16, 17 Genetic experiments in yeast revealed that deletion of all three kinases is required to completely abolish SNF1 activity. Interrogation of sequence databases revealed that the most closely related mammalian kinases to the yeast kinases were members of the CaMKK family, followed by a protein kinase termed LKB1. Interestingly, mutations in the gene coding for LKB1 had been shown previously to lead to a cancer predisposition syndrome in humans called PeutzJeghers syndrome, 18, 19 although little was known about the biochemical properties of LKB1, or its downstream targets. At this point, the AMPK research community took an almost unanimous step to follow the lead that LKB1 was the best candidate for the upstream kinase in the AMPK cascade. The reasons for this were based on previous studies that had apparently discounted CaMKK family members in the regulation of AMPK: CaMKK purified from pig brain only weakly phosphorylated AMPK in vitro; AMPK kinase purified from rat liver was not activated by Ca 2 þ -calmodulin and did not bind to calmodulin-Sepharose; and AMPK kinase from rat liver only weakly phosphorylated Ca 2 þ /calmodulindependent protein kinase I, a downstream substrate for CaMKK. 20 With the benefit of hindsight there is now a good explanation that can account for all of these observations, without the necessity to exclude CaMKK as an AMPK kinase. 
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However, at the time, the field turned to LKB1 as the candidate for the elusive AMPK kinase.
Evidence that LKB1 is upstream of AMPK LKB1 was shown to account for the AMPK kinase activity purified from rat liver. 21, 22 Interestingly, LKB1, like AMPK, is a heterotrimeric kinase and requires binding of MO25 and STE-20 related adaptor protein for activity. In vitro, purified recombinant LKB1 complex directly phosphorylates AMPK on Thr-172, leading to activation. In cells lacking LKB1 expression, for example, HeLa, activation of AMPK in response to stimuli that increase the AMP/ATP ratio, or following incubation with 5 amino-4-imidazolecarboxamide riboside, is abolished. 21 This observation suggests that LKB1
is required for the activation of AMPK in response to elevated AMP (or ZMP, a closely related AMP mimetic). Previous studies using the AMPK kinase preparation from rat liver, which subsequently was shown to correspond to LKB1 complex, reported that it was activated directly by AMP. 20 However, using peptide substrates for LKB1 this has not been substantiated. Furthermore, AMP was proposed to promote phosphorylation of Thr-172 by LKB1, 20 however, recent studies have challenged this concept. Two independent studies have demonstrated that AMP does not promote phosphorylation of AMPK by recombinant preparations of LKB1. 12, 14 One explanation for the apparent discrepancy between the earlier studies and these more recent studies is that the preparations of AMPK and LKB1 from the rat liver may have contained protein phosphatase 2C. 12 AMP inhibits dephosphorylation of AMPK 12, 14, 23 and so the effect of AMP on phosphorylation observed in the earlier studies may have been due to inhibition of dephosphorylation, rather than activation of phosphorylation. LKB1 activity is not altered by conditions that increase AMPK activity in cells and appears to be constitutively active. 22, 24 A possible mechanism by which an increase in AMP leads to increased phosphorylation of AMPK would be via inhibition of the dephosphorylation step. Such a mechanism could account for the observation that LKB1 is required for the AMP-dependent activation of AMPK in cells (see Figure 2) . It is also possible that LKB1 is regulated through other mechanisms, for example, changes in subcellular localization and/or association with MO25 and STE-20 related adaptor protein.
In the past couple of years a number of animal models in which LKB1 has been deleted in specific tissues have been investigated. In skeletal muscle, deletion of LKB1 almost completely abolishes AMPKa2 activity in response to contraction, 5 amino-4-imidazolecarboxamide riboside or phenformin (a close relative of the antidiabetic drug, metformin). 25 The activity of a1-containing AMPK complexes, although reduced, was not completely abolished. Similarly, in heart, deletion of LKB1 almost completely abolished AMPKa2 activation in response to ischaemia, whereas the activity of AMPKa1 was reduced by only a small degree. 26 These findings indicate that LKB1 is the predominant upstream kinase for AMPKa2 activation in skeletal muscle and heart, but that other kinases act on AMPKa1 in these tissues. In an elegant study, Shaw et al. reported that deletion of LKB1 in adult liver significantly reduces total AMPK activity. 27 Taken together with the finding that LKB1
accounts for virtually all of the AMPK kinase activity in liver, these findings suggest that LKB1 is the predominant upstream kinase for both AMPKa1 and a2 in liver.
Evidence that CaMKKb is upstream of AMPK
Although LKB1 was shown to be a major kinase acting upstream of AMPK in a number of tissues, several lines of evidence indicated that other upstream kinases could activate AMPK. In cells lacking LKB1, AMPK activity (and Thr-172 phosphorylation) was not abolished. Moreover, AMPK could be activated by a number of stimuli in cells lacking LKB1 expression. 28, 29 Three independent studies reported that CaMKK phosphorylates and activates AMPK in vitro. Two of these studies provided evidence that CaMKKb, rather than CaMKKa, is the predominant kinase acting on AMPK, although a role for CaMKKa cannot be excluded at this time. As mentioned previously, studies on AMPK kinase in the 1990s appeared to exclude members of the CaMKK family from acting on AMPK. However, this can now be explained as those earlier studies used an AMPK kinase preparation purified from rat liver, and this activity corresponds to LKB1. Studies using CaMKK purified from rat brain suggested that AMP promotes phosphorylation of AMPK by CaMKK. 20 However, more recent studies suggest that this is probably not the case. 28, 29 CaMKKb is activated by an increase in intracellular Ca 2 þ suggesting that AMPK may be activated by stimuli that signal through Ca 2 þ as a second messenger. Two recent studies provide evidence that this is indeed the case. In primary human endothelial cells, thrombin activates AMPK via an increase in Ca 2 þ and activation of CaMKKb. 30 Similarly, in T lymphocytes, AMPK is activated in response to triggering of the T-cell antigen receptor by a Ca 2 þ and CaMKKb-dependent mechanism. 31 Importantly, in both these studies, activation of AMPK occurred in the absence of a detectable increase in AMP, and in the case of stimulation in response to thrombin, inhibition of LKB1 had no effect on AMPK activation. 30 One potential physiological role for the activation of AMPK by CaMKKb-dependent signalling is to prepare the cell for an increase in energy demand. This would be advantageous for the cell under conditions where the rise in intracellular Ca 2 þ signalled an increase in energy utilization. A model showing activation of AMPK by either LKB1 or CaMKKb is shown in Figure 2 .
Other kinases upstream of AMPK activation in mammalian cells
In yeast, three kinases upstream of SNF1 have been identified, raising the possibility that in mammalian cells at least three activating AMPK kinases might exist. Recently, evidence that a third AMPK kinase is present in mammals has been reported. Tak1, a member of the mitogen activated protein kinase kinase kinase family, was shown to phosphorylate and activate AMPK in vitro. 32 To date, however, the physiological significance of AMPK activation by Tak1 is unclear and further studies are required to reveal the role of Tak1 in regulating AMPK in vivo. Furthermore, the possibility that other AMPK kinases exist in mammals should not be discounted.
Future directions
A key goal in the future is to determine the contributions of LKB1 and CaMKKb (and potentially other upstream AMPK-activating kinases) in the activation of AMPK in vivo. This will involve determining the role of the different upstream kinases in activation of AMPK in response to various stimuli and their role in different tissues. Furthermore, the possibility that different AMPK isoform complexes could be differentially activated by the upstream kinases adds another tier of complexity to the system.
